Inovio Historical Balance Sheet
INO Stock | USD 4.35 0.03 0.69% |
Trend analysis of Inovio Pharmaceuticals balance sheet accounts such as Total Current Liabilities of 23.4 M or Total Stockholder Equity of 95.2 M provides information on Inovio Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Inovio Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Inovio Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Inovio Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Inovio Pharmaceuticals is a good buy for the upcoming year.
Inovio Pharmaceuticals Inventory |
|
Inovio |
About Inovio Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Inovio Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Inovio Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Inovio Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Inovio currently owns. An asset can also be divided into two categories, current and non-current.
Inovio Pharmaceuticals Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Inovio Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Inovio Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Inovio Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Inovio Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most accounts from Inovio Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Inovio Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.At this time, Inovio Pharmaceuticals' Other Stockholder Equity is very stable compared to the past year. As of the 2nd of December 2024, Property Plant And Equipment Gross is likely to grow to about 37.1 M, while Total Assets are likely to drop about 131.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 33.0M | 32.1M | 30.2M | 21.9M | Total Assets | 495.9M | 348.5M | 172.9M | 131.2M |
Inovio Pharmaceuticals balance sheet Correlations
Click cells to compare fundamentals
Inovio Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Inovio Pharmaceuticals balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 144.0M | 539.8M | 495.9M | 348.5M | 172.9M | 131.2M | |
Total Current Liabilities | 32.0M | 41.7M | 65.7M | 96.9M | 42.6M | 23.4M | |
Total Stockholder Equity | 3.4M | 461.1M | 399.7M | 222.4M | 117.3M | 95.2M | |
Property Plant And Equipment Net | 26.6M | 24.1M | 29.0M | 18.0M | 14.5M | 7.5M | |
Net Debt | 77.3M | (211.7M) | (38.1M) | (14.3M) | 15.9M | 16.7M | |
Retained Earnings | (739.8M) | (906.2M) | (1.2B) | (1.5B) | (1.6B) | (1.5B) | |
Accounts Payable | 7.6M | 1.5M | 28.0M | 21.1M | 4.6M | 5.0M | |
Cash | 22.2M | 250.7M | 71.1M | 46.3M | 14.3M | 13.6M | |
Non Current Assets Total | 49.8M | 68.6M | 47.5M | 33.3M | 19.8M | 28.2M | |
Cash And Short Term Investments | 89.5M | 411.6M | 401.3M | 253.0M | 145.3M | 92.0M | |
Net Receivables | 2.0M | 19.1M | 8.0M | 11.7M | 2.4M | 3.9M | |
Common Stock Shares Outstanding | 8.2M | 12.9M | 17.4M | 19.9M | 22.2M | 28.0M | |
Liabilities And Stockholders Equity | 144.0M | 539.8M | 495.9M | 348.5M | 172.9M | 131.2M | |
Non Current Liabilities Total | 106.6M | 36.9M | 30.5M | 29.3M | 13.0M | 12.1M | |
Other Current Assets | 2.6M | 40.5M | 39.1M | 50.5M | 5.4M | 6.9M | |
Other Stockholder Equity | 742.6M | 1.4B | 1.6B | 1.7B | 1.7B | 1.8B | |
Total Liab | 138.5M | 78.6M | 96.3M | 126.2M | 55.6M | 35.5M | |
Property Plant And Equipment Gross | 26.6M | 24.1M | 48.0M | 18.0M | 35.3M | 37.1M | |
Total Current Assets | 94.2M | 471.2M | 448.4M | 315.2M | 153.1M | 103.0M | |
Accumulated Other Comprehensive Income | 472.6K | (256.2K) | (282.2K) | (698.7K) | (662.6K) | (629.5K) | |
Intangible Assets | 3.7M | 3.1M | 2.6M | 2.1M | 2.4M | 2.3M | |
Other Current Liab | 22.1M | 37.9M | 35.1M | 73.0M | 18.7M | 11.5M | |
Other Liab | 9.1M | 206.4K | 111.2K | 32.0K | 36.9K | 35.0K | |
Non Currrent Assets Other | (5.4M) | 22.2M | (1.5M) | (1.6M) | 2.6M | 2.7M | |
Other Assets | 2.7M | 43.6M | 1.4M | 684.0K | 1.0 | 0.95 | |
Common Stock Total Equity | 101.4K | 186.9K | 217.4K | 253.1K | 227.8K | 216.4K | |
Common Stock | 101.4K | 186.9K | 217.4K | 253.1K | 22.8K | 21.7K | |
Property Plant Equipment | 12.8M | 11.3M | 17.5M | 7.7M | 8.9M | 5.2M | |
Current Deferred Revenue | 124.1K | 46.6K | 21.6K | 1.0M | 1.2M | 2.1M | |
Short Term Investments | 67.3M | 160.9M | 330.2M | 206.7M | 131.0M | 85.0M | |
Net Tangible Assets | (10.8M) | 447.5M | 386.5M | 209.7M | 241.2M | 159.6M | |
Retained Earnings Total Equity | (739.8M) | (906.2M) | (1.2B) | (1.5B) | (1.3B) | (1.3B) | |
Capital Surpluse | 742.6M | 1.4B | 1.6B | 1.7B | 2.0B | 2.1B |
Pair Trading with Inovio Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Inovio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inovio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Inovio Stock
Moving against Inovio Stock
0.78 | VCYT | Veracyte | PairCorr |
0.72 | VERA | Vera Therapeutics | PairCorr |
0.66 | SABSW | SAB Biotherapeutics | PairCorr |
0.57 | DRUG | Bright Minds Biosciences Trending | PairCorr |
0.51 | VCEL | Vericel Corp Ord | PairCorr |
The ability to find closely correlated positions to Inovio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Inovio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Inovio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Inovio Pharmaceuticals to buy it.
The correlation of Inovio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Inovio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Inovio Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Inovio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.43) | Revenue Per Share 0.025 | Quarterly Revenue Growth (0.55) | Return On Assets (0.40) | Return On Equity (0.91) |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.